Baillie Gifford & CO Guardant Health, Inc. Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
A detailed history of Baillie Gifford & CO transactions in Guardant Health, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 5,872,024 shares of GH stock, worth $186 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
5,872,024
Previous 6,093,286
3.63%
Holding current value
$186 Million
Previous $176 Million
23.49%
% of portfolio
0.1%
Previous 0.14%
Shares
4 transactions
Others Institutions Holding GH
# of Institutions
323Shares Held
127MCall Options Held
844KPut Options Held
2.38M-
Vanguard Group Inc Valley Forge, PA11.7MShares$371 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.2MShares$356 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.1MShares$321 Million0.04% of portfolio
-
Cadian Capital Management, LP New York, NY6.93MShares$219 Million8.13% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$190 Million5.07% of portfolio
About Guardant Health, Inc.
- Ticker GH
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 102,220,000
- Market Cap $3.24B
- Description
- Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...